key: cord-0055193-agi65vux
authors: Fineman, Stanley M.; Lee, Gerald; Mahr, Todd; Chipps, Bradley E.
title: From the Pages of Allergy Watch
date: 2021-01-13
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.01.005
sha: ad63e72fab95d6318ab6aec14bc8423014b1b073
doc_id: 55193
cord_uid: agi65vux

nan

14 15 Along with other chronic airway diseases, asthma has been considered a likely risk factor for severe 16 . Surprisingly, initial studies from China did not show more severe illness in patients with 17 asthma or respiratory allergy. One explanation could be that allergic disease is associated with lower 18 expression of the SARS-CoV-2 receptor ACE2. Airway cell expression of ACE2 was studied in three 19 cohorts of carefully phenotyped children and adults with asthma or allergic disease. In 318 children from 20 the Urban Environment and Childhood Asthma (URECA) cohort, allergic sensitization was inversely 21 related to ACE2 expression in the nasal epithelium, independent of asthma status. Among asthmatic 22 children, moderate and high allergic sensitization were linked to progressively greater reductions in 23 ACE2 expression, compared to no or minimal sensitization. Higher ACE2 was also associated with lower 24 J o u r n a l P r e -p r o o f 2 levels of type 2 biomarkers, including number of positive specific IgE results and total IgE. In a study of 25 24 adults with allergic rhinitis, experimental cat allergen challenges -nasal challenge and in an 26 environmental exposure chamber -were followed by reductions in ACE2 expression. In a cohort of 23 27 adults with mild asthma not receiving asthma controller therapy, allergen bronchoprovocation to dust 28 mite, ragweed, or cat was associated with reduced ACE2 expression in the lower airway epithelium. The 29 findings suggest that respiratory allergy and allergen challenge are associated with reduced ACE2 30 expression. ACE2 expression is lowest in subjects with asthma and high levels of allergic sensitization but addressed in a meta-analysis of patient-level data from studies that measured eNO before stepping-106 down ICS. A systematic review identified eight observational studies or randomized controlled trials in 107 which adult patients (12 years or older) with asthma receiving low-or moderate-dose ICS underwent 108 eNO measurement before ICS dose reduction. Data on 384 participants from seven studies were 109 included in a mixed effects multilevel meta-analysis, for the primary outcome of exacerbations within 12 110 weeks after ICS step-down. Patients in four studies underwent 50% reduction of ICS dose, while ICS 111 treatment was withdrawn in three studies. In about one-half of patients, eNO was 20 ppb or less. The 112 rate of acute exacerbations within 12 weeks of step-down was 11.2%. On meta-analysis, patients with a

The use of eNO as a stepdown strategy in mild to moderate asthma is 124 receiving more attention. In patients who have a T2-high signal in their airways, exhaled NO greater 125 than 50 ppb has been shown to be a cutoff above which stepdown therapy should not be attempted

These data can be used to help payers understand the need to cover exhaled NO as an adjunct to the 127 management of patients with significant reactive airway disease